Ichnos Glenmark Innovation subsidiary IGI Therapeutics has signed an exclusive licensing agreement with AbbVie for ISB 2001, ...

The deal hands AbbVie a drug that’s shown early promise in multiple myeloma and may be useful treating other cancers and ...

AbbVie has placed a high price on that potential, coughing up $700 million for a phase 1 candidate and offering up to $1.225 ...

AbbVie (ABBV) and IGI Therapeutics SA have entered into an exclusive licensing agreement for the latter’s lead ...

AbbVie licensed IGI's trispecific myeloma drug ISB 2001 in a deal worth up to $1.925 billion following strong early-phase ...

The antibody, ISB 2001, is currently in Phase 1 clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM) ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the most undervalued large cap stocks to buy according to analysts. On ...

It is the second licensing deal that AbbVie has negotiated this year for a trispecific for multiple myeloma, coming in the ...

During early drug development and preclinical development, researchers use in vitro cultured lymphocytes to induce cytokine ...

Glenmark Pharma share price today: Shares of Glenmark Pharma surged 10 per cent, recording a 52-week high of ₹2,094.40 on ...

Given the advantages over its rivals, Regeneron is hopeful its bispecific antibody will become the new standard of care for ...

Regeneron Pharmaceuticals said on Wednesday the U.S. Food and Drug Administration has approved its drug for a type of blood ...